Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHD
17 nov. 2016 08h00 HE
|
Neos Therapeutics, Inc
DALLAS/FORT WORTH, Texas, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics Reports Third Quarter 2016 Financial Results
10 nov. 2016 07h00 HE
|
Neos Therapeutics, Inc
DALLAS/FORT WORTH, Texas, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Present at Stifel 2016 Healthcare Conference
08 nov. 2016 08h00 HE
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics to Host Third Quarter 2016 Financial Results Conference Call on November 10, 2016
03 nov. 2016 08h00 HE
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients Six Years and Older
16 mai 2016 06h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR)...